Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Insulin Delivery

Medtronic to Acquire Companion Medical; Thoughts on What It Could Mean for Insulin Delivery

Here is a brief preview of this blast: Medtronic announced plans to acquire privately-held Companion Medical and its InPen connected insulin pen platform. According to the press release, the acquisition is expected to close within the next 1-2 months, and terms were undisclosed. Below, FENIX provides thoughts on the Companion Medical acquisition, Medtronic’s first under new President Sean Salmon, and additional insight into possible strategy changes that could affect other insulin delivery stakeholders (e.g. Novo Nordisk, Lilly, Sanofi, Dexcom, Tandem, Insulet, Beta Bionics, and especially Bigfoot+Abbott).

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.